LENZ Therapeutics Inc (LENZ) News

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100...

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

Reported positive topline data from Phase 3 CLARITY study for presbyopia; selected LNZ100 as lead candidate; New Drug Application submission...

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage...

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

– LNZ100 selected as lead candidate – Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater...

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

 Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a...